Transconjunctival Sutureless 25-Gauge Vitrectomy
TSV-25G
1 other identifier
interventional
14
1 country
1
Brief Summary
The aim of this study was to evaluate the role of 25-gauge transconjuntival sutureless vitrectomy (TSV) in patients with persistent vitreous floaters who underwent multifocal intraocular lens (IOL) implantation.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for phase_3
Started Jan 2007
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2007
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2008
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2008
CompletedFirst Submitted
Initial submission to the registry
March 26, 2009
CompletedFirst Posted
Study publicly available on registry
March 27, 2009
CompletedMarch 27, 2009
March 1, 2009
1.1 years
March 26, 2009
March 26, 2009
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
The aim of this study was to evaluate the role of 25-gauge transconjuntival sutureless vitrectomy (TSV) in patients with persistent vitreous floaters who underwent multifocal intraocular lens (IOL) implantation
1 year
Study Arms (2)
1
EXPERIMENTALMultifocal IOL implant associated with vitreous opacities that underwent 25-gauge vitrectomy were prospectively analyzed.
2
EXPERIMENTALMultifocal IOL implantation without transconjunctival vitrectomy
Interventions
Multifocal IOL implantation without transconjunctival vitrectomy
Eligibility Criteria
You may qualify if:
- disabling vitreous floaters
- Age-related cataract Unsatisfactory correction with glasses
You may not qualify if:
- central endothelial cell count less than 2000 cells/mm2
- glaucoma or intraocular pressure greater than 21 mmHg
- amblyopia
- retinal abnormalities
- diabetes mellitus
- steroid or immunosuppressive treatment
- connective tissue diseases
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Hospital Oftalmologico de Brasilia
Brasília, Federal District, 70000, Brazil
MeSH Terms
Conditions
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
PATRICK TZELIKIS, PhD
Federal University of Minas Gerais
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
March 26, 2009
First Posted
March 27, 2009
Study Start
January 1, 2007
Primary Completion
February 1, 2008
Study Completion
December 1, 2008
Last Updated
March 27, 2009
Record last verified: 2009-03